The extra domain B of fibronectin (ED-B) is identical between mice and humans; therefore, Nilsson and colleagues showed that targeting the ED-B domain by an antibody fragment combined with the tTF led to selectively targeting tumor blood vessels in vivo. Here, RHOH is linked to neoplasm.